Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Recurrent Ovarian Cancer (Immunoreactive Subtype)
NCT03732950Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2019
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Overall Response Rate at 2 years. Started Mar 2019; status: active, not recruiting.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03732950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732950.